痘苗病毒致炎兔皮提取物(Analgecine) - 药物靶点：5-HT receptor x bradykinin receptor_在研适应症：神经痛，疼痛，背痛_专利_临床

概要

基本信息

药物类型

生物药

别名

AGC、Analgecine (Vanway Pharmaceutical)、Extracts from Rabbit Skin Inflamed by Vaccinia Virus

+ [2]

靶点

5-HT receptor x bradykinin receptor

作用方式

调节剂、拮抗剂

作用机制

5-HT receptor调节剂(5-羟色胺受体调节剂)、bradykinin receptor拮抗剂(Bradykinin receptors antagonists)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

威世药业（如皋）有限公司宏威製藥集團有限公司

非在研机构-

最高研发阶段批准上市

首次获批日期

中国 (2003-12-09),

背痛

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

关联

6

项与痘苗病毒致炎兔皮提取物相关的临床试验

CTR20191965

/ Completed临床1期

在健康受试者中评价痘苗病毒致炎兔皮提取物注射液多次剂量递增的随机双盲安慰剂对照的安全性和耐受性研究

评价健康受试者多次静脉滴注痘苗病毒致炎兔皮提取物注射液的安全性和耐受性。

开始日期2019-11-14

申办/合作机构

威世药业（如皋）有限公司

CTR20182066

/ Completed临床1期

在健康受试者中评价痘苗病毒致炎兔皮提取物注射液单次剂量递增的随机双盲安慰剂对照的安全性和耐受性研究

评价健康受试者单次静脉滴注痘苗病毒致炎兔皮提取物注射液的安全性和耐受性。

开始日期2019-01-14

申办/合作机构

威世药业（如皋）有限公司

NCT02168010

/ Completed临床3期

Efficacy and Safety of Analgecine for Low Back Pain: a Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Trial

The study examines the efficacy and safety of Analgecine in the treatment of chronic pain in patients with low back pain for 3 months after surgical treatment. It is a randomized, placebo-controlled, double blind, multi-center phase III clinical trial. Patients with chronic low back pain for 3 months after surgical treatment is recruited (age between 18 and 70; pain visual analysis scale (VAS) between 3 and 8). After randomization, subjects are divided into 3 groups: 1) Treatment with Analgecine (Experiment group); 2) Treatment with Neurotropin (positive control group); 3) Placebo group. Subjects will be undergone 4 measurement time points on day 0, 7, 14, and 21. In each time points, subjects are required to score their pain with pain VAS and to have regular blood, urine, and renal/liver function tests. The changes of the pain VAS at day 21 are compared between groups.

开始日期2013-10-01

申办/合作机构

威世药业（如皋）有限公司

100 项与痘苗病毒致炎兔皮提取物相关的临床结果

登录后查看更多信息

100 项与痘苗病毒致炎兔皮提取物相关的转化医学

登录后查看更多信息

100 项与痘苗病毒致炎兔皮提取物相关的专利（医药）

登录后查看更多信息

42

项与痘苗病毒致炎兔皮提取物相关的文献（医药）

2023-06-07·Physics in Medicine & Biology

Evaluating the effect of setup uncertainty reduction and adaptation to geometric changes on normal tissue complication probability using online adaptive head and neck intensity modulated proton therapy

Article

作者: Sharp, Gregory C ; Lalonde, Arthur ; Chamseddine, Ibrahim ; Paganetti, Harald ; Bobić, Mislav ; Winey, Brian

AbstractObjective. To evaluate the impact of setup uncertainty reduction (SUR) and adaptation to geometrical changes (AGC) on normal tissue complication probability (NTCP) when using online adaptive head and neck intensity modulated proton therapy (IMPT). Approach. A cohort of ten retrospective head and neck cancer patients with daily scatter corrected cone-beam CT (CBCT) was studied. For each patient, two IMPT treatment plans were created: one with a 3 mm setup uncertainty robustness setting and one with no explicit setup robustness. Both plans were recalculated on the daily CBCT considering three scenarios: the robust plan without adaptation, the non-robust plan without adaptation and the non-robust plan with daily online adaptation. Online-adaptation was simulated using an in-house developed workflow based on GPU-accelerated Monte Carlo dose calculation and partial spot-intensity re-optimization. Dose distributions associated with each scenario were accumulated on the planning CT, where NTCP models for six toxicities were applied. NTCP values from each scenario were intercompared to quantify the reduction in toxicity risk induced by SUR alone, AGC alone and SUR and AGC combined. Finally, a decision tree was implemented to assess the clinical significance of the toxicity reduction associated with each mechanism. Main results. For most patients, clinically meaningful NTCP reductions were only achieved when SUR and AGC were performed together. In these conditions, total reductions in NTCP of up to 30.48 pp were obtained, with noticeable NTCP reductions for aspiration, dysphagia and xerostomia (mean reductions of 8.25, 5.42 and 5.12 pp respectively). While SUR had a generally larger impact than AGC on NTCP reductions, SUR alone did not induce clinically meaningful toxicity reductions in any patient, compared to only one for AGC alone. Significance Online adaptive head and neck proton therapy can only yield clinically significant reductions in the risk of long-term side effects when combining the benefits of SUR and AGC.

2023-06-01·Heliyon

Effects of land use types on the depth distribution of selected soil properties in two contrasting agro-climatic zones

Article

作者: Sime, Getachew ; Gonfa, Yadessa ; Ababu, Tadesse ; Teramage, Mengistu T ; Demissie, Ambachew ; Feyissa, Abate ; Asfaw, Meto

The depth distribution of soil properties are governed by several interacting factors including land use types (LUT) and agro-climate (AgC) factors. Yet, there is little information on the effects of LUT, AgC and their combination on soil properties along depth, which this study aimed to investigate. We collected a total of 36 composite soil samples using the manual percussion of a steel core tube layer by layer vertically up to 30 cm in sites representing both highland and lowlands, and analyzed for selected soil properties. A significant main effects of LUT on the depth distribution of bulk density (BD), Ca, Na, K and Cu, and AgC on soil texture, pH, EC, Ca, Na, K, P, Mn, Fe and Cu were noted. The two-way ANOVA analysis also revealed the significant effects of both LUT and AgC on the depth distribution of BD, Na, K, Cu and EC, reflecting their influences on the paths associated to bio-geo-recycling processes. Compared to crop and forestlands, the average SOC and Fe were lower while EC, CEC, Ca, Na, K, P, Mn and Zn were higher in homegarden located in highland than lowland, possibly the acid nature of the highland soil may make the extractable cations available. SOC was not significantly influenced by AgC, LUT and their interaction effect. Based on the Elemental Enrichment Ratio (EER), the SOC was concentrated in the upper surface soil in forest and cropland located both in highland (1.79, 1.33) and lowland (1.80, 1.57), respectively. The reverse propagation pattern SOC depth distribution in soils under homegarden with EER of 0.7 (highland) ad 0.8 (lowland) showed that implementing such system can accelerate carbon sinking and safely store it in subsoil. Also, diversified species composition associated with respective root architectures in the homegarden system, make it an efficient soil nutrient management, which should be widely promoted.

2023-06-01·Molecular Genetics and Metabolism Reports

Exogenous aralar/slc25a12 can replace citrin/slc25a13 as malate aspartate shuttle component in liver

Article

作者: García-Picazo, Alberto ; Santamaría-Cano, Andrea ; Martínez-Chantar, María Luz ; Martín, Miguel Á ; Vázquez, Jesús ; Satrústegui, Jorgina ; Saheki, Takeyori ; González-Aseguinolaza, Gloria ; Paradela, Alberto ; Calvo, Enrique ; Del Arco, Araceli ; González-Moreno, Luis ; Contreras, Laura ; Pérez-Carreras, Mercedes

The deficiency of CITRIN, the liver mitochondrial aspartate-glutamate carrier (AGC), is the cause of four human clinical phenotypes, neonatal intrahepatic cholestasis caused by CITRIN deficiency (NICCD), silent period, failure to thrive and dyslipidemia caused by CITRIN deficiency (FTTDCD), and citrullinemia type II (CTLN2). Clinical symptoms can be traced back to disruption of the malate-aspartate shuttle due to the lack of citrin. A potential therapy for this condition is the expression of aralar, the AGC present in brain, to replace citrin. To explore this possibility we have first verified that the NADH/NAD⁺ ratio increases in hepatocytes from citrin(-/-) mice, and then found that exogenous aralar expression reversed the increase in NADH/NAD⁺ observed in these cells. Liver mitochondria from citrin (-/-) mice expressing liver specific transgenic aralar had a small (~ 4-6 nmoles x mg prot^-1 x min^-1) but consistent increase in malate aspartate shuttle (MAS) activity over that of citrin(-/-) mice. These results support the functional replacement between AGCs in the liver. To explore the significance of AGC replacement in human therapy we studied the relative levels of citrin and aralar in mouse and human liver through absolute quantification proteomics. We report that mouse liver has relatively high aralar levels (citrin/aralar molar ratio of 7.8), whereas human liver is virtually devoid of aralar (CITRIN/ARALAR ratio of 397). This large difference in endogenous aralar levels partly explains the high residual MAS activity in liver of citrin(-/-) mice and why they fail to recapitulate the human disease, but supports the benefit of increasing aralar expression to improve the redox balance capacity of human liver, as an effective therapy for CITRIN deficiency.

100 项与痘苗病毒致炎兔皮提取物相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	V	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
神经痛	中国	威世药业（如皋）有限公司	2004-03-23
疼痛	中国	威世药业（如皋）有限公司	2004-03-23
背痛	中国	宏威製藥集團有限公司	2003-12-09

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
椎间盘疾病	临床3期	中国	威世药业（如皋）有限公司	2021-10-11
腰痛	临床3期	中国	威世药业（如皋）有限公司	2013-10-01
急性缺血性卒中	临床2期	中国	威世药业（如皋）有限公司	2022-07-15
颈部疼痛	临床1期	中国	威世药业（如皋）有限公司	2019-11-18
肩痛	临床1期	中国	威世药业（如皋）有限公司	2019-11-18
颈、肩、臂综合征	临床1期	中国	威世药业（如皋）有限公司	2019-01-14
神经痛	临床1期	-	威世药业（如皋）有限公司	2005-08-01